Therapeutic Antibodies in Hematology: Advances in Malignant and Non-Malignant Disorders
Cells · 2025
DOI: 10.3390/cells15010046 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, 2025. Verfasst von Hiroshi Yasui und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan. Hauptthemen laut MEDLINE: Hematologic Neoplasms, Hematology, Hematologic Diseases. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI, the Practical Research Project for Rare/Intractable Diseases of the Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Therapeutic antibodies have revolutionized hematology, offering targeted and effective treatments for both malignant and non-malignant diseases. In hematologic malignancies, anti-CD20, anti-CD19, anti-CD38, and anti–B-cell maturation antigen (BCMA) antibodies have markedly improved survival outcomes, whereas antibody–drug conjugates and bispecific antibodies continue to expand therapeutic possibilities. Besides cancer, complement inhibitors such as eculizumab, ravulizumab, and the recently approved crovalimab have redefined paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome management, and the bispecific antibody emicizumab has transformed prophylaxis in hemophilia A. Furthermore, novel antibody formats such as the trifunctional anti-CD38 × CD3 antibody (Tri-31C2) exhibit enhanced anti-myeloma activity compared to chimeric CD38 antibodies, underscoring the future potential of T-cell–redirecting designs. This review summarizes key developments in therapeutic antibodies for hematological disorders, their action mechanisms, and emerging strategies to further optimize their efficacy and safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Oncology, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan.
- The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
- Division of Medical Genome Sciences, Department of Genomic and Preventive Medicine, School of Medicine, Sapporo Medical University, Sapporo 060-8556, Japan.
- Department of Hematology, Japanese Red Cross Medical Center, Tokyo 150-8935, Japan.
- Sapporo Medical University, Sapporo 060-8556, Japan.
- Institute for Genetic Medicine, Hokkaido University, Sapporo 060-0808, Japan.
ORCID-Profile: Hiroshi Yasui, Masashi Idogawa, Tadao Ishida
Förderung
- JSPS KAKENHI
- the Practical Research Project for Rare/Intractable Diseases of the Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
- Practical Research Project for Rare/Intractable Diseases of the Japan Agency for Medical Research and Development
Zitieren
APA
Yasui, H., Idogawa, M., Ishida, T., & Imai, K. (2025). Therapeutic Antibodies in Hematology: Advances in Malignant and Non-Malignant Disorders. Cells. https://doi.org/10.3390/cells15010046
Vancouver
Yasui H, Idogawa M, Ishida T, Imai K. Therapeutic Antibodies in Hematology: Advances in Malignant and Non-Malignant Disorders. Cells. 2025. doi:10.3390/cells15010046
BibTeX
@article{Yasui2025,
author = {Yasui, Hiroshi and Idogawa, Masashi and Ishida, Tadao and Imai, Kohzoh},
title = {Therapeutic Antibodies in Hematology: Advances in Malignant and Non-Malignant Disorders},
journal = {Cells},
year = {2025},
doi = {10.3390/cells15010046}
}
EUVIMED